Creating a city-wide cohort of HIV-infected individuals in Washington, DC

Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort

Observational George Washington University · NCT01206920

This study is creating a big database of people living with HIV in Washington, DC, to help improve their care and health outcomes by collecting and sharing important information from different clinics.

Quick facts

Study typeObservational
Enrollment19000 (estimated)
SexAll
SponsorGeorge Washington University Academic / other
Locations14 sites (Washington D.C., District of Columbia and 13 other locations)
Trial IDNCT01206920 on ClinicalTrials.gov

What this trial studies

The DC Cohort aims to establish a comprehensive, clinic-based longitudinal database of HIV-infected individuals receiving care in Washington, DC. This initiative will involve major community and academic clinics, collecting data on socio-demographics, risk factors, treatments, diagnoses, and clinical outcomes. The cohort will facilitate routine reporting and analytic support to improve the quality of care and clinical outcomes for patients with HIV/AIDS. By comparing data across various clinics, the project seeks to enhance understanding and management of HIV in the region.

Who should consider this trial

Good fit: Ideal candidates for this cohort are individuals aged 18 and older receiving care for HIV at participating clinics in Washington, DC.

Not a fit: Patients who are unable or refuse to provide informed consent, or minors unaware of their HIV status, may not benefit from this cohort.

Why it matters

Potential benefit: If successful, this cohort could significantly improve the quality of care and clinical outcomes for HIV-infected patients in Washington, DC.

How similar studies have performed: Other studies have successfully established similar cohorts, indicating that this approach is both tested and valuable for improving HIV care.

Eligibility criteria

Show full inclusion / exclusion criteria
Treatment Cohort Inclusion Criteria:

* Patient is receiving care for HIV at one or more of the twelve participating clinics in the DC Cohort.
* Patient is either age 18 years or older, or seeks HIV care independently and is able to understand and sign informed consent.
* Patient is a minor who is consented by a parent or legal guardian.

Treatment Cohort Exclusion Criteria:

* Patient is unable or refuses to provide informed consent.
* Minor children ages 12 through 17 who are unaware of their HIV status

Prevention Cohort Inclusion Criteria:

Persons receiving any antiretroviral prescription without evidence of HIV or Hepatitis B infection

* PrEP (e.g., TDF/FTC, Descovy, Apretude)
* Combination ART indicative of nPEP in an HIV-uninfected person
* Persons receiving an antiretroviral prescription indicative of DoxyPEP Doxycycline 200mg PO taken within 72 hrs of unprotected sexual encounter (or variations thereof where clearly not prescribed as a treatment course)
* Test positive for ≥1 bacterial STI (positive gonorrhea (GC/NG) or chlamydia (CT) test or positive syphilis test requiring treatment within one year)

  * 2 bacterial STI (GC, chlamydia, syphilis) tests at 2 or more different encounters
  * 2 HIV tests at 2 or more different encounters
* Patient requesting PrEP at their clinical visit
* Patient requesting nPEP at their clinical visit
* People who identify as injecting drugs

Patients with a Z29.81 Encounter for HIV pre-exposure prophylaxis

Where this trial is running

Washington D.C., District of Columbia and 13 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions HIVAIDSCo-morbidities
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.